BiolineRx is a clinical stage biopharmaceutical development company with a focus on identifying, in-licensing, and developing therapeutic candidates that address largely unmet medical needs. BLRX’s development pipeline is made up of clinical-stage therapeutic candidates, includes but is not limited to BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease and BL-8020, an orally available treatment for the hepatitis C virus and other viral indications. For more information, visit the company’s website at www.biolinerx.com/